Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

Description

Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP.

Conditions

Hiv

Talk to us

Study Overview

On this page

Study Details

Study overview

Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP.

Real World Clinical Outcomes in Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP: An Observational, Multisite Prospective 2 Year Study in the Southern U.S.

Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

Condition
Hiv
Intervention / Treatment

-

Contacts and Locations

Orlando

Midway Specialty Care Center, Orlando, Florida, United States, 32819

Temple Terrace

Midway Specialty Care Center, Temple Terrace, Florida, United States, 33617

West Palm Beach

Midway Specialty Care Center, West Palm Beach, Florida, United States, 33401

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Cisgender females, ages 18 years and older
  • 2. Negative HIV test at baseline
  • 3. Negative Pregnancy test at baseline
  • 4. Weigh at least 35 kilograms
  • 5. Already Prescribed CAB-LA (Apretude)
  • 1. Transgender females or males
  • 2. Cisgender males
  • 3. Cisgender female who is actively breastfeeding
  • 4. Severe hepatotoxicity
  • 5. Evidence of Hepatitis B Infection
  • 6. History or presence of allergies to cabotegravir or its components

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Midway Specialty Care Center,

Study Record Dates

2027-03-31